Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E34.12 EPS (ttm)10.57 Insider Own0.10% Shs Outstand236.16M Perf Week4.70%
Market Cap85.18B Forward P/E22.15 EPS next Y16.28 Insider Trans-2.48% Shs Float235.94M Perf Month18.79%
Income2.51B PEG1.61 EPS next Q3.78 Inst Own92.10% Short Float1.05% Perf Quarter9.37%
Sales9.03B P/S9.43 EPS this Y35.60% Inst Trans-0.25% Short Ratio1.51 Perf Half Y15.06%
Book/sh44.14 P/B8.17 EPS next Y20.32% ROA19.80% Target Price377.48 Perf Year30.11%
Cash/sh7.88 P/C45.76 EPS next 5Y21.20% ROE26.60% 52W Range270.62 - 358.89 Perf YTD29.01%
Dividend- P/FCF32.53 EPS past 5Y24.10% ROI20.70% 52W High0.50% Beta1.05
Dividend %- Quick Ratio1.90 Sales past 5Y11.10% Gross Margin87.50% 52W Low33.28% ATR11.23
Employees6850 Current Ratio2.30 Sales Q/Q37.40% Oper. Margin37.70% RSI (14)68.09 Volatility4.50% 2.96%
OptionableYes Debt/Eq0.06 EPS Q/Q76.60% Profit Margin27.80% Rel Volume2.21 Prev Close353.70
ShortableYes LT Debt/Eq0.06 EarningsOct 22 BMO Payout0.00% Avg Volume1.65M Price360.67
Recom2.00 SMA209.91% SMA5012.63% SMA20013.47% Volume3,635,519 Change1.97%
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Dec-12-13Reiterated Argus Buy $280 → $310
Oct-30-13Initiated FBR Capital Mkt Perform $259
Oct-29-13Reiterated Barclays Overweight $240 → $262
Jul-17-13Reiterated Barclays Overweight $220 → $240
Dec-19-14 11:31AM  Roche Drugs For Alzheimer's, Breast Cancer Disappoint at Investor's Business Daily
10:46AM  Cramer: Downside to Biotech as ImmunoGen Stock Cut in Half at TheStreet
Dec-18-14 06:13PM  Cramer's perfect recipe for a Santa Claus rally at CNBC +6.25%
04:22PM  Juiced By Fed, Stocks Rocket Higher; Biogen Up 6% at Investor's Business Daily
02:52PM  Stocks Hold Near Session Highs; FedEx Bounces Back at Investor's Business Daily
Dec-17-14 06:57PM  Lightning Round: Good stock with a good yield at CNBC
12:01AM  Harvard Scientist Lights Up Neurons to Find Brain Cures Bloomberg
Dec-15-14 04:44PM  Where is Santa rally? Yahoo Finance Blogs
09:34AM  Biotech Entrepreneur Tony Coles Takes Aim At Parkinson's And Alzheimer's at Forbes
05:49AM  Alder Biopharmaceuticals Slumps: ALDR Falls 5.5% in Session Zacks
Dec-13-14 08:02AM  Meet 5 Top Biotech Stocks Holding Up In Shaky Market at Investor's Business Daily
Dec-12-14 04:20PM  Teva's (TEVA) 2015 Guidance Hit By Generics Zacks
07:31AM  Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% Zacks
06:04AM  Alder Biopharmaceuticals Inc. (ALDR) in Focus: Stock Soars 31.9% Zacks
05:47AM  Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% Zacks
Dec-11-14 03:10PM  PDL BioPharma's Q4 Revenues to Rise Y/Y on Higher Royalties Zacks
02:25PM  Lilly Upgraded On 2 Potential Blockbuster Drugs at Investor's Business Daily
01:02PM  The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley Benzinga
08:27AM  Biogen Idec (BIIB) Stock: Moving Average Crossover Alert Zacks
07:45AM  Ophthotech Corporation (OPHT) Jumps: Stock Gains 5% Zacks
Dec-10-14 02:10PM  Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data Zacks
12:30PM  Myriad Genetics Unveils Positive Cancer Study Results Zacks
10:00AM  Are Investors Signaling Optimism in Biotechs Through Short Interest? at 24/7 Wall St.
06:46AM  Avalanche Biotechnologies (AAVL) Jumps: Stock Adds 6.1% in Session Zacks
Dec-09-14 05:20PM  Dynavax & AstraZeneca Alter Agreement for Asthma Product Zacks
03:40PM  Celgene Up on Positive Revlimid Data Presented at ASH Zacks
07:39AM  Rexahn Pharmaceuticals, Inc. (RNN) Rises: Stock Up 8.6% Zacks
05:50AM  bluebird bio (BLUE) in Focus: Stock Surges 9.4% Zacks
Dec-08-14 05:50PM  Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks
01:12PM  Midday movers: McDonald's, Sony, Celgene & more at CNBC
08:05AM  Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% Zacks
07:59AM  Compugen (CGEN) Worth Watching: Stock Moves 8.8% Higher Zacks
06:51AM  Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% Zacks
Dec-05-14 12:00PM  Incyte's Jakafi Gets FDA Approval for Polycythemia Vera Zacks
09:20AM  Bayer Files Hemophilia A Drug Marketing Application in EU Zacks
07:03AM  Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3% Zacks
Dec-04-14 06:50PM  Lightning Round: Time to buy buy buy for 2015 at CNBC
05:45PM  Amgen's Blincyto Gets FDA Nod, Carries Boxed Warning Zacks
04:47PM  Hot Drugmakers Build More Labs, Grab Space In Boston Investor's Business Daily
04:47PM  Hot Drugmakers Build More Labs, Grab Space In Boston at Investor's Business Daily
02:00PM  Array BioPharma Regains Binimetinib Rights from Novartis Zacks
12:32PM  Will New Alzheimer's Drug Boost Biogen? at Investor's Business Daily
11:52AM  Stock Market Today: Stocks Worsen Near Midday; Airlines Rally at Investor's Business Daily
08:06AM  Can the Rally in Biogen (BIIB) Shares Continue? Zacks
07:50AM  Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% Zacks
05:54AM  ADMA Biologics Slumps: ADMA Tanks 11% in Session Zacks
05:37AM  Prothena Corporation (PRTA) Falls: Stock Goes Down 5% Zacks
Dec-03-14 06:16PM  Cramer's big discovery under the market's hood at CNBC +5.81%
04:31PM  Record territory again for the Dow Industrials Yahoo Finance Blogs
04:25PM  Stock Market Today: Indexes Close Near Day's Highs at Investor's Business Daily
02:10PM  Actelion Submits Marketing Application for Uptravi in EU Zacks
01:33PM  Biogen Up on Encouraging Interim Data on Alzheimer's Drug Zacks
12:36PM  Great News For Biogen, But What's Next For The Stock? Benzinga
12:31PM  Third Quarter Earnings Season in Review: Sector Winners and Losers, the Misleading Record Beat Rate, and the Outlook for Q4 Yahoo Finance Blogs
12:29PM  Jim Cramer on the Stock Market: You Have to Love Biotech at TheStreet
12:26PM  Wednesday's midday movers: Apple, Kraft & more at CNBC
12:05PM  Biogen Idec is Now Piper Jaffray's Second Favorite Biotech at Barrons.com
10:21AM  Biogen and its Alzheimer's Drug: What the Wags are Saying at The Wall Street Journal
09:51AM  Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study Zacks
07:00AM  Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE and ALPROLIX┬« at ASH Annual Meeting Business Wire
06:33AM  Biogen Idec (BIIB) Shows Strength: Stock Moves 6.4% Up Zacks
05:35AM  Why Biogen Idec (BIIB) is Poised to Beat Earnings Estimates Zacks
Dec-02-14 08:21PM  Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners at TheStreet +6.43%
07:07PM  Cramer Remix: The best stocks to own now at CNBC
06:33PM  Cramer's heated love affair with biotech at CNBC
05:18PM  Early Tests Go Well For Biogen's Drug To Slow Alzheimer's Investor's Business Daily
05:10PM  Biogen climbs after 'promising' trial at Financial Times
05:06PM  Biogen Shares Rise on Outlook for Alzheimer's Treatment at The Wall Street Journal
05:00PM  7 Biotech stocks to buy now CNBC
04:30PM  Energy Stocks Shake Off Plunging Oil Prices to Push the Dow to New Highs at TheStreet
04:07PM  Biogen Will Push Alzheimers Drug to Phase 3 Bloomberg
03:22PM  Biogen Alzheimers drug skips to Phase 3 testing at MarketWatch
03:02PM  US STOCKS-Energy shares lead Wall St higher in broad advance Reuters
02:54PM  Stock Market Today: Indexes Trade Near Session Highs at Investor's Business Daily
02:30PM  AstraZeneca/Eli Lilly Start Mid-Stage Alzheimer's Study Zacks
02:02PM  Biogen Thrills Street as Alzheimer Results Shine at Barrons.com
01:15PM  Deutsche Bank Sees More Upside For Biogen Benzinga
12:43PM  Midday movers: Biogen Idec, Priceline, BP & more at CNBC
12:23PM  Biogen Alzheimer's Drug Succeeding In Early Tests at Investor's Business Daily
12:15PM  GM's smokin sales, Obama aids Taser and Biogen Idec attacking Alzheimer's Yahoo Finance
11:19AM  Biogen Idec: 'Own Long Term for Pipeline Events,' RBC Says at Barrons.com
11:02AM  Stock Market Today Opens Higher; FedEx, Biogen, Cypress Surge at Investor's Business Daily
10:02AM  Biogen Up Sharply On Promising Alzheimer's Results Benzinga
09:46AM  Biogen shares up; Alzheimer's drug shows promise at CNBC
09:27AM  Biogen's stock surges on upbeat outlook for Alzheimer's treatment at MarketWatch
09:23AM  Cramer's Mad Dash: Love CY & BIIB CNBC
09:17AM  Biogen Rises on Results of Early-Stage Alzheimers Drug Trial at Bloomberg
07:48AM  Intra-Cellular Therapies (ITCI) Jumps: Stock Rises 6.8% Zacks
Dec-01-14 11:44AM  Novartis' Gilenya Fails To Treat Progressive MS at Investor's Business Daily
08:52AM  Ken Fisher: Why I Hate Annuities at Forbes
Nov-28-14 04:00PM  Alexion's Soliris Gets Final Positive NICE Recommendation Zacks
05:35AM  Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% Zacks
04:39AM  Prosensa Holding N.V. (RNA) Jumps: Stock Rises 8.6% Zacks
Nov-26-14 04:00PM  Isis Pharmaceuticals Earns Milestone on Study Initiation Zacks
09:54AM  Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval Zacks
Nov-25-14 01:18PM  Midday movers: Apple, Netflix, Comcast & more at CNBC
11:46AM  Biogens Tecfidera Label Updated After Rare Brain Infection Case at Bloomberg
06:18AM  Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% Zacks
Nov-24-14 03:20PM  Immunomedics' Veltuzumab Receives Orphan Drug Status Zacks
07:18AM  Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% Zacks
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn's disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company's products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM
SCANGOS GEORGE AChief Executive OfficerMar 03Sale335.792,942987,89454,389Mar 04 03:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 26Sale342.171,048358,59421,407Feb 27 04:19 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 23Option Exercise0.001,988023,395Feb 25 02:21 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 23Option Exercise0.002,598026,706Feb 25 02:17 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.004,280017,473Feb 25 02:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.003,821023,930Feb 25 02:07 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 18Sale327.901,222400,6949,412Feb 19 04:23 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 13Sale316.42425134,47821,407Feb 14 04:42 PM
SCANGOS GEORGE AChief Executive OfficerFeb 13Sale316.81486153,97057,331Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 13Sale316.811,290408,6850Feb 14 04:36 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.002,246012,998Feb 14 04:33 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.003,573013,166Feb 14 04:48 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.002,807014,517Feb 14 04:46 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.002,142021,119Feb 14 04:43 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.0071401,941Feb 14 04:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.00792014,459Feb 14 04:42 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.002,142011,644Feb 14 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.009,189062,150Feb 14 04:37 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.002,24602,246Feb 14 04:36 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.003150690Feb 14 04:38 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.002,246025,167Feb 14 04:34 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 11Sale314.312,085655,33613,667Feb 12 05:03 PM
SCANGOS GEORGE AChief Executive OfficerFeb 11Sale314.312,456771,94552,961Feb 12 05:00 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833064,297Feb 11 07:55 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270050,314Feb 11 07:55 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,824011,613Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691013,922Feb 11 07:49 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,346Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691025,133Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909020,723Feb 11 06:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,636011,032Feb 11 07:52 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191010,278Feb 11 07:49 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468011,229Feb 11 07:47 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,705010,778Feb 11 07:45 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277014,944Feb 11 07:43 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023021,883Feb 11 06:07 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498017,633Feb 11 06:07 PM
DiPietro KennethEVP Human ResourcesFeb 04Sale299.011,655494,8620Feb 05 04:36 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 03 05:29 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,15909,730Feb 03 05:25 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 01Option Exercise0.004,586010,097Feb 03 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,159010,044Feb 03 05:15 PM
Rowinsky Eric KDirectorJan 21Sale310.092,020626,38210,440Jan 22 04:49 PM
YOUNG WILLIAMDirectorJan 08Sale285.1115,0004,276,59018,509Jan 09 04:24 PM
PANGIA ROBERT WDirectorJan 06Option Exercise47.556,250297,18820,253Jan 07 12:22 PM
PANGIA ROBERT WDirectorJan 06Sale278.036,2501,737,68814,003Jan 07 12:22 PM
SHERWIN STEPHEN ADirectorJan 02Option Exercise59.825,500329,0109,460Jan 06 11:19 AM
SHERWIN STEPHEN ADirectorJan 02Sale279.285,5001,536,0593,960Jan 06 11:19 AM